AcelRx Pharmaceuticals, Inc. (ACRX)
| Market Cap | 144.11M |
| Revenue (ttm) | 5.54M |
| Net Income (ttm) | -33.41M |
| Shares Out | 113.26M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $1.18 |
| Previous Close | $1.21 |
| Change ($) | -0.03 |
| Change (%) | -2.48% |
| Day's Open | 1.20 |
| Day's Range | 1.16 - 1.21 |
| Day's Volume | 425,832 |
| 52-Week Range | 1.02 - 2.94 |
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February...
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the ...
NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of ...
BENSALEM, Pa., July 28, 2021 /PRNewswire/ -- Law Offices of Howard G.
NEW YORK, July 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020...
LOS ANGELES, July 23, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the class action filed on b...
LOS ANGELES, July 21, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Ac...
New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between...
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of ...
New York, New York--(Newsfile Corp. - July 17, 2021) - WHY: New York, N.Y., July 17, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceutica...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February...
AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.
Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News an...
New York, New York--(Newsfile Corp. - July 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between...
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to provide a license to Laboratoire Aguettant to commercialize Dzuveo in Europe and give AcelRx two prefilled syringe product candidates for the U.S....
HAYWARD, Calif., July 14, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...
New York, New York--(Newsfile Corp. - July 13, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX)...
San Diego, California and Hayward, California--(Newsfile Corp. - July 8, 2021) - Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers ...
NEW YORK, July 4, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 ...
SAN DIEGO & HAYWARD, Calif.--(BUSINESS WIRE)---- $ACRX #ACELRX--Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therape...
BENSALEM, Pa., July 1, 2021 /PRNewswire/ -- Law Offices of Howard G.
New York, New York--(Newsfile Corp. - June 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between...
LOS ANGELES, June 25, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Ac...
New York, New York--(Newsfile Corp. - June 24, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or ...
NEW YORK--(BUSINESS WIRE)-- #ACRX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and ...
LOS ANGELES, June 23, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the class action filed on be...
NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of ...
NEW YORK, June 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the C...
HAYWARD, Calif., June 17, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...
NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of ...
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purc...
Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified American Express Company among others.
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
SAN DIEGO & HAYWARD, Calif.--(BUSINESS WIRE)---- $ACRX #ACRX--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc...
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf o...
NEW YORK, June 11, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmac...
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #ACRX--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
BENSALEM, Pa.--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AcelRx Pharmaceuticals, In...
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...
NEW YORK, June 10, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("Ac...
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $ACRX #ACRX--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
BENSALEM, Pa.--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) inve...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmaceuticals, Inc...
NEW YORK--(BUSINESS WIRE)-- #AcelRX--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District ...
NEW YORK, June 8, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of i...
HAYWARD, Calif., June 1, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative the...
HAYWARD, Calif., May 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative the...
About ACRX
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Feb 14, 2011 |
| CEO Vincent Angotti | Employees 54 |
| Stock Exchange NASDAQ | Ticker Symbol ACRX |
Financial Performance
In 2020, ACRX's revenue was $5.42 million, an increase of 136.61% compared to the previous year's $2.29 million. Losses were -$40.38 million, -24.16% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 6.67, which is an increase of 465.25% from the latest price.